Sociedad Americana de Hirudoterapia

Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes

Research article published in Journal of controlled release : official journal of the Controlled Release Society (2008)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Desarrollo de fármacosSeguridad y control de infeccionesFarmacología salivalMeng M et al. · Journal of controlled release : official journal of the Controlled Release Society, 2008

Abstract

Two biodegradable cationic lipids, stearylamine and DC-Chol, were chosen to investigate the effect of cationic lipids on the in vitro and in vivo characteristics of hydrophilic proteins or peptides of low isoelectric point. Thrombin inhibitor recombinant hirudin variant-2 (rHV2) was selected as the model drug. The cationic lipids were found to achieve higher entrapment efficiency of rHV2 in liposomes than zwitterionic lipids. The positively charged liposomes became less positive and relatively stable in serum after loading rHV2. The cationic liposomes induced sustained release of rHV2 in the presence of plasma, significantly prolonged the antithrombotic efficacy and plasma level of rHV2 after intravenous injection in rats in comparison with neutral lipid liposomes, especially for stearylamine group. Both clotting times correlated well with plasma rHV2 levels. No serious adverse events were observed and physical state of rats was satisfactory for all the formulations. Electrostatic interaction between negative charge of rHV2 and cationic liposomes was confirmed and it might affect all the characteristics of rHV2 loaded cationic vehicles. The findings suggest that cationic liposomes may be a potential sustained-release delivery system for parenteral administration of hydrophilic proteins or peptides with low isoelectric point to prolong efficacy and improve bioavailability.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAminesAnimalsBiological AvailabilityBlood CoagulationCationsCholesterolFibrinolytic AgentsHirudinsInfusions, ParenteralLecithinsMalePartial Thromboplastin Time

Resumen

Two biodegradable cationic lipids, stearylamine and DC-Chol, were chosen to investigate the effect of cationic lipids on the in vitro and in vivo characteristics of hydrophilic proteins or peptides of low isoelectric point.

Por qué esto importa para la hirudoterapia

This study investigated whether cationic liposomes (stearylamine and DC-Chol) could improve the delivery of recombinant hirudin variant-2 (rHV2), described in the abstract as a negatively charged thrombin inhibitor and model drug, in rats. Cationic liposomes achieved higher entrapment, induced sustained rHV2 release in plasma, and significantly prolonged antithrombotic efficacy and plasma rHV2 levels after intravenous injection versus neutral liposomes, with the stearylamine group showing the strongest effect. This may be relevant to ASH's domain because hirudin is widely recognized as a leech-derived anticoagulant, though the abstract itself does not state this origin. This is a preclinical animal study with no leeches involved, focused on drug delivery technology rather than hirudotherapy.

Citación

Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes

Meng M et al. · Journal of controlled release : official journal of the Controlled Release Society, 2008

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.